Australian team develops simple PD (Parkinson's disease) blood test:
This article was originally published in Clinica
Executive Summary
Australian researchers from the Howard Florey Institute, in Melbourne, are developing a simple blood test for diagnosing Parkinson's disease (PD) before symptoms appear. The test, which works by measuring levels of the brain-secreted protein alpha-synuclein, is the second PD development to be announced by the group in the last few months. The team has previously said that it is developing a gene-based test for PD (see Clinica No 1252, p 23). The new test has a broader application by screening for many different types of PD, monitoring treatment, and measuring the effectiveness of drugs being developed to treat the condition. It is being trialled in a large-scale study. Funding is also being sought to further develop the test, which the group believes could become available for clinical use within the next two years.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.